ERBB2 and breast cancer: The NCCN guidelines for breast cancer treatment encourage HR‐positive, HER2‐negative early invasive breast cancer patients to undergo testing using multigene assays with or without adjuvant systemic therapy based on nodal status and other clinicopathological features.4